Eli Lilly’s Alzheimer’s trek; Novo Nordisk puts down US roots; Sarepta and gene therapy accelerated approvals; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Hel­lo March! To round out Feb­ru­ary, we take a deep look at the wind­ing his­to­ry of an Alzheimer’s drug on the brink of ap­proval, US reg­u­la­tors’ lat­est think­ing on ac­cel­er­at­ed ap­provals, next steps for some of the biggest names in phar­ma, and more. Oh, and as of this writ­ing, $XBI is still hov­er­ing above $100 — a thresh­old the in­dex fi­nal­ly crossed this week af­ter a two-year lull.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.